MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.hroo.2025.12.022

Медицинская библиотека · Heart rhythm O2 · 2026

Personalized in vitro models reveal functional impact of a KCNH2 mutation and enable drug screening in LQTS2.

Zheng Bingyu, Zhu Yue, Sun Mingyu, Cheng Hongyi, Zhang Shimeng, Cai Cheng, Gu Kai, An Yanzun, Ding Xiangwei, Zhang Feng, Cui Chang, Chen Minglong

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Long QT syndrome is clinically associated with recurrent ventricular tachycardia and sudden cardiac death. Mutations in KCNH2, which encodes the pore-forming potassium channel subunit human ether-a-go-go-related gene (Kv11.1), are associated with long QT syndrome type 2 (LQTS2).

OBJECTIVE

We aimed to investigate the pathogenicity and personalized therapy for a patient with LQTS2 carrying a novel KCNH2 heterozygous mutation F431L.

METHODS

This study aimed to evaluate the expression and function of the channel protein, we conducted immunoblotting and whole-cell patch-clamp recordings. In addition, patient-specific human-induced pluripotent stem cell-derived cardiomyocytes were combined with a heart-on-chip platform to validate the pathogenicity of this heterozygous variant and investigate the pharmacologic candidates for phenotypic rescue.

RESULTS

In HEK293 cells overexpressing the mutant KCNH2, a significant reduction in human ether-a-go-go-related gene membrane abundance was observed. The heterozygous variant led to decreased current density and alterations in voltage-dependent activation (positively shifted) and inactivation (negatively shifted) compared with the wild type. Correspondingly, patient-specific human-induced pluripotent stem cell-derived cardiomyocytes harboring the heterozygous KCNH2 F431L mutation displayed reduced current density and prolonged action potential duration. Moreover, LQTS2 patient-specific engineered cardiac tissues replicated the disease phenotype with extended field potential duration. Drug screening on the heart-on-chip platform indicated the potential therapeutic efficacy of the slowly activating delayed rectifier potassium current channel agonist ML277 and the proteasome inhibitor MG101.

CONCLUSION

The F431L mutation in KCNH2 was pathogenic, characterized by both channel instability and functional impairments. Our study also highlighted the feasibility of using a patient-specific microphysiological system for individualized treatment in ion-channel diseases.

Для цитирования: Zheng Bingyu, Zhu Yue, Sun Mingyu, Cheng Hongyi, Zhang Shimeng, Cai Cheng, Gu Kai, An Yanzun, Ding Xiangwei, Zhang Feng, Cui Chang, Chen Minglong. Personalized in vitro models reveal functional impact of a KCNH2 mutation and enable drug screening in LQTS2.. Heart rhythm O2. 2026. DOI: 10.1016/j.hroo.2025.12.022.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.